An innovative approach to involve patients in measuring treatment effects in drug trials

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 8, 2006, Pages 1117-1118

  Kaduszkiewicz, Hanna ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; PLACEBO;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL; COGNITION; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; GOAL ATTAINMENT; HUMAN; NOTE; OUTCOME ASSESSMENT; THERAPY; TREATMENT DURATION; BIOASSAY; CONTROLLED CLINICAL TRIAL; MOTIVATION; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; ENDPOINT DETERMINATION; GALANTAMINE; GOALS; HUMANS; PSYCHOMETRICS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33645903517     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060261     Document Type: Note

References (4)

1. Birks J. Cholinesterase inhibitors for Alzheimer's disease [Cochrane review]. In: The Cochrane Library; Issue 1, 2006. Oxford; Update Software
2. Schneider LS. AD2000: Donepezil in Alzheimer's disease. Lancet 2004;363:2100-1.
3. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005;331:321-7.
4. Rockwood K, Fay S, Song X, et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ 2006;174(8):1099-105.